2022 Western Medical Research Conference
International Union Against Tuberculosis And Lung Disease
MGM Resorts is known for its impressive collection of properties in Las Vegas and other top destinations, offering a wide range of options for meeting and event planners. But what truly sets MGM Resorts apart is its unwavering commitment to providing exceptional amenities while acting as a responsible host in its resort operations: Mandalay Bay Mandalay Bay, known for its vast meeting facilities, offers over 2.1 million square feet of space to accommodate events of all sizes. Atop the convention center, one of America's largest contiguous rooftop solar arrays harnesses the power of the sun to generate clean energy. . The Food & Beverage teams at Delano at Mandalay Bay use upcycled glass containers and sourcing produce from onsite gardens, promoting a circular economy and reducing waste. These initiatives have earned Mandalay Bay prestigious green certifications, including five Green Keys, four Green Key Meetings, and four Green Globes for Existing Buildings. MGM Grand Las Vegas MGM Grand, with its expansive meeting space of over 850,000 square feet, places a strong emphasis on health and wellness offerings for its guests. It boasts the world's largest portfolio of StayWell® guest rooms and meeting rooms, providing a unique experience for wellness-oriented events. Energy efficiency is a key focus at MGM Grand, with the implementation of energy-efficient lighting, heating, and cooling systems throughout the property. Towel and linen reuse programs are in place to conserve water and reduce the resort's environmental footprint. MGM Grand has been recognized with four Green Keys, five Green Keys for Meetings, and four Green Globes for Existing Buildings. ARIA Resort & Casino ARIA Resort & Casino features over 500,000 square feet of meeting space, accompanied by an abundance of naturally lit and outdoor options. Its onsite cogeneration plant efficiently generates approximately 30% of its electricity needs while utilizing waste heat to warm water. ARIA has also achieved six LEED Gold certifications, making it the largest privately funded LEED Gold certified development upon its opening. Sustainable wood from Forest Stewardship Council (FSC) certified forests is prioritized in the resort's construction. ARIA's energy-efficient design measures result in a remarkable 30% reduction in energy use. Bellagio Bellagio, renowned for its elegance and iconic attractions, offers 200,000 square feet of meeting space that combines imagination, sophistication, and creativity. The Fountains of Bellagio are fed with water sourced from onsite wells, reducing reliance on the Colorado River. The Conservatory at Bellagio showcases nature through stunning seasonal displays, with a focus on composting 90% of trees, flowers, and plants after use. Bellagio has been awarded five Green Keys, the highest level of certification from Green Key Global Hotel and Meetings Programs. MGM Resorts leads the way in sustainable hospitality, proving that exceptional experiences and responsible hosting can go hand in hand. Meeting and event planners can confidently choose MGM Resorts, knowing they are partnering with a company that not only offers outstanding amenities but also shares their commitment to creating a more sustainable future.
Doomsday Postponed? Preventing And Reversing Epidemics Of Drug-resistant Tuberculosis
Raviglione, M. C. & Uplekar, M. W. WHO's new stop TB strategy. Lancet 367, 952–955 (2006).
World Health Organization. Anti-tuberculosis drug resistance in the world: report no. 3 (WHO, Geneva, 2004).
Singh, J. A., Upshur, R. & Padayatchi, N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 4, e50 (2007).
Koenig, R. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 319, 894–897 (2008).
Jones, K. D., Hesketh, T. & Yudkin, J. Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. Trans. R. Soc. Trop. Med. Hyg. 102, 219–224 (2008).
World Health Organization. Anti-tuberculosis drug resistance in the world: report no. 4 (WHO, Geneva, 2008).
von Gottberg, A. Et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 371, 1108–1113 (2008).
Hancock, R. E. W. The end of an era? Nature Rev. Drug Discov. 6, 28 (2007).
Raviglione, M. XDR-TB: entering the post-antibiotic era? Int. J. Tuberc. Lung Dis. 10, 1185–1187 (2006).
Norrby, S. R., Nord, C. E. & Finch, R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115–119 (2005).
Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nature Med. 10, S122–S129 (2004).
Spigelman, M. K. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196 (Suppl. 1), 28–34 (2007).
Glickman, S. W., Rasiel, E. B., Hamilton, C. D., Kubataev, A. & Schulman, K. A. A portfolio model of drug development for tuberculosis. Science 311, 1246–1247 (2006).
Dye, C. & Espinal, M. A. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B 268, 45–52 (2001).
World Health Organization. The global MDR-TB and XDR-TB response plan 2007–2008 (WHO, Geneva, 2007).
Dye, C., Espinal, M. A., Watt, C. J., Mbiaga, C. & Williams, B. G. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 185, 1197–1202 (2002).
Zignol, M. Et al. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194, 479–485 (2006).
Cohen, T. Et al. Challenges in estimating the total burden of drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 177, 1302–1306 (2008).
Ben Amor, Y., Nemser, B., Singh, A., Sankin, A. & Schluger, N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg. Infect. Dis. 14, 1345–1352 (2008).
Shah, N. S. Et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13, 380–387 (2007).
Pillay, M. & Sturm, A. W. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45, 1409–1414 (2007).
Gandhi, N. R. Et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575–1580 (2006).
Dye, C. & Espinal, M. A. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B 268, 45–52 (2001).
Dye, C. & Williams, B. G. Criteria for the control of drug-resistant tuberculosis. Proc. Natl Acad. Sci. USA 97, 8180–8185 (2000).
Dye, C., Williams, B. G., Espinal, M. A. & Raviglione, M. C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295, 2042–2046 (2002).
Cohen, T., Sommers, B. & Murray, M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3, 13–21 (2003).
Martinez, J. L., Baquero, F. & Andersson, D. I. Predicting antibiotic resistance. Nature Rev. Microbiol. 5, 958–965 (2007).
Rosas-Magallanes, V. Et al. Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis. Mol. Biol. Evol. 23, 1129–1135 (2006).
Coros, A., DeConno, E. & Derbyshire, K. M. IS6110, a Mycobacterium tuberculosis complex-specific insertion sequence, is also present in the genome of Mycobacterium smegmatis, suggestive of lateral gene transfer among mycobacterial species. J. Bacteriol. 190, 3408–3410 (2008).
Becq, J. Et al. Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli. Mol. Biol. Evol. 24, 1861–1871 (2007).
Hazbon, M. H. Et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 2640–2649 (2006).
Prammananan, T. Et al. Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. Clin. Microbiol. Infect. 14, 446–453 (2008).
Caws, M. Et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 4, e1000034 (2008).
Espinal, M. A. Et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. J. Am. Med. Assoc. 283, 2537–2545 (2000).
Mak, A. Et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am. J. Respir. Crit. Care Med. 178, 306–312 (2008).
Cox, H. Et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med. 3, e384 (2006).
Cox, H. S. Et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin. Infect. Dis. 44, 1421–1427 (2007).
Nathanson, E. Et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg. Infect. Dis. 12, 1389–1397 (2006).
Leimane, V. Et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365, 318–326 (2005).
Furin, J. The clinical management of drug-resistant tuberculosis. Curr. Opin. Pulm. Med. 13, 212–217 (2007).
Shin, S. S. Et al. Long-term follow-up for multidrug-resistant tuberculosis. Emerg. Infect. Dis. 12, 687–688 (2006).
Keshavjee, S. Et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372, 1403–1409 (2008).
Mitnick, C. S. Et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359, 563–574 (2008).
World Health Organization. Global tuberculosis control 2008: surveillance, planning, financing (WHO, Geneva, 2008).
World Health Organization. Green Light Committee Initiative. Annual report (WHO, Geneva, 2007).
Kwon, Y. S. Et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis. 47, 496–502 (2008).
Bonilla, C. A. Et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One 3, e2957 (2008).
Cox, H. S., Morrow, M. & Deutschmann, P. W. Long term efficacy of DOTS regimens for tuberculosis: systematic review. Br. Med. J. 336, 484–487 (2008).
Chan, E. D., Strand, M. J. & Iseman, M. D. Treatment outcomes in extensively resistant tuberculosis. N. Engl. J. Med. 359, 657–659 (2008).
Mariam, D. H., Mengistu, Y., Hoffner, S. E. & Andersson, D. I. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48, 1289–1294 (2004).
Gagneux, S. Et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312, 1944–1946 (2006).
Strauss, O. J. Et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J. Clin. Microbiol. 46, 1514–1516 (2008).
European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12, 736–743 (2006).
Sun, Y. J. Et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Intern. J. Tuberc. Lung Dis. 11, 436–442 (2007).
Cox, H. S. Et al. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir. Res. 6, 134 (2005).
Marais, B. J. Et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J. Clin. Microbiol. 44, 3539–3543 (2006).
Lopez, B. Et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exper. Immunol. 133, 30–37 (2003).
Toungoussova, O. S., Caugant, D. A., Sandven, P., Mariandyshev, A. O. & Bjune, G. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol. Med. Microbiol. 42, 281–290 (2004).
Blower, S. & Supervie, V. Predicting the future of XDR tuberculosis. Lancet Infect. Dis. 7, 443 (2007).
Cohen, T. & Murray, M. Modeling epidemics of multidrug-resistant M. Tuberculosis of heterogeneous fitness. Nature Med. 10, 1117–1121 (2004).
Blower, S. M. & Chou, T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nature Med. 10, 1111–1116 (2004).
DeRiemer, K. Et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365, 1239–1245 (2005).
Espinal, M. A. & Dye, C. Can DOTS control multidrug-resistant tuberculosis? Lancet 365, 1206–1209 (2005).
Wu, P. Et al. Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005. Thorax 63, 312–316 (2008).
Dye, C. In Clinical Tuberculosis 4th edn (eds Davies, P. D. O., Barnes, P. F. & Gordon, S. B.) 21–41 (Hodder Arnold, London, 2008).
Dye, C., Garnett, G. P., Sleeman, K. & Williams, B. G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352, 1886–1891 (1998).
Styblo, K. & Bumgarner, J. R. Tuberculosis can be controlled with existing technologies: evidence. Tubercul. Surveill. Res. Unit. Progress Report 2, 60–72 (1991).
Nardell, E. A. Environmental infection control of tuberculosis. Semin. Respir. Infect. 18, 307–319 (2003).
Bock, N. N., Jensen, P. A., Miller, B. & Nardell, E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J. Infect. Dis. 196 (Suppl. 1), 108–113 (2007).
World Health Organization. Tuberculosis infection control in the era of expanding care and treatment (WHO, Geneva, 2007).
World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis (WHO, Geneva, 2006).
Cobelens, F. G. Et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 5, e150 (2008).
Mitnick, C. D., Appleton, S. C. & Shin, S. S. Epidemiology and treatment of multidrug resistant tuberculosis. Semin. Respir. Crit. Care Med. 29, 499–524 (2008).
Nunn, A. J., Phillips, P. P. & Gillespie, S. H. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb.) 88 (Suppl. 1), 85–92 (2008).
Borgdorff, M. W., Floyd, K. & Broekmans, J. F. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull. World Health Organ. 80, 217–227 (2002).
Styblo, K. Epidemiology of Tuberculosis (KNCV Tuberculosis Foundation, The Hague, 1991).
China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 364, 417–422 (2004).
Dye, C., Ottmani, S., Laasri, L. & Bencheikh, N. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int. J. Tuberc. Lung Dis. 11, 1225–1231 (2007).
Suarez, P. G. Et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J. Infect. Dis. 184, 473–478 (2001).
The Fight Against AIDS, Tuberculosis And Malaria : Past Progress And Hope For The Future
ERROR: The request could not be satisfiedRequest blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation.
Generated by cloudfront (CloudFront) Request ID: fy7wABn2q3gAosIBQFg6sb8LGP_jYPcLjfVhO3cyrA9QSUolkR0Wcg==
Comments
Post a Comment